SCHEMBL5447258

SCHEMBL5447258

CC1(C)OB(c2cccc3c(Nc4ccc5ncccc5c4)nccc23)OC1(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.46
▸ TGFBR1 P36897 2/20 0.45
▸ GRM4 Q14833 1/20 0.42
▸ ERBB2 P04626 1/20 0.41
▸ ERBB4 Q15303 1/20 0.41
▸ FAAH O00519 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ ABCC1 P33527 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ STK10 O94804 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444076 0.76 CA9 (0.48) EGFR
SCHEMBL4505968 0.76 EGFR (0.54) EGFRTGFBR1GRM4ERBB2ERBB4
SCHEMBL14564295 0.76 EGFR (0.34) EGFRMEN1KMT2AALDH1A1
SCHEMBL4508756 0.73 EGFR (0.59) EGFRTGFBR1GRM4ERBB2ERBB4
SCHEMBL481508 0.73 MAPT (0.42) EGFRMAPTMEN1POLBKMT2A
SCHEMBL29982045 0.73 MAPT (0.42) EGFRMAPTMEN1POLBKMT2A
SCHEMBL5447665 0.72 EGFR (0.49) EGFRTGFBR1GRM4ERBB2ERBB4
SCHEMBL27344950 0.72 CYP3A4 (0.39) EGFRMAPTMEN1KMT2AHTT
SCHEMBL5437478 0.71 ABCG2 (0.48) EGFRTGFBR1GRM4ERBB2ERBB4
SCHEMBL31577390 0.70 LMNA (0.44) MAPTMEN1NPC1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 — — US disclosed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 — — EP disclosed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 EGFR 1404/4885TGFBR1 1311/4885GRM4 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback